Purine nucleosides and nucleotides are widely distributed substances that exhibit a diverse range of effects in a number of tissues, acting as important extracellular signalling molecules in addition to their more established roles in cellular metabolism. They mediate their effects via activation of distinct cell surface receptors, termed adenosine (or P1) and P2 purinergic receptors. Although roles for adenosine and adenine nucleotides have been described previously in the pituitary gland, the distribution of the receptor subtypes and the effects of their activation on pituitary function are not well defined. Recent evidence, however, has emerged to describe a complex signalling system for purines in the pituitary gland. Data from a variety of studies have shown that the expression pattern, number and affinity of adenosine and/or P2 receptors may be cell-type specific and that non-endocrine in addition to endocrine cells elaborate these receptors. These variations, along with the diverse range of signalling pathways activated, dictate the response of individual cell types to extracellular purines, with roles now emerging for these substances in the regulation of hormone release, pituitary cell proliferation and cytokine/growth factor expression. In this review, we discuss these advances and examine some implications for pituitary growth control and the response of the hypothalamic-pituitary-adrenal axis to stress and inflammation.
INTRODUCTION AND HISTORICAL ASPECTS
Extracellular purines (adenosine, AMP, ADP and ATP) and pyrimidines (UDP and UTP) are important signalling molecules that mediate their effects via specific cell surface receptors. The concept of purinergic compounds as signal substances was first introduced as long ago as 1929 when Drury and Szent-Gyo$ rgyi [1] described potent effects of AMP and adenosine from heart muscle extracts on arterial dilatation, blood pressure regulation and intestinal contraction. In 1934, Gillespie [2] expanded on these observations and demonstrated different effects of adenosine and ATP in inducing contraction of guinea coupling of purine release to metabolic demands by local control of blood flow has since been extended to other adenine nucleotides, such as ATP that is released during skeletal muscle contraction [8, 9] , and thus forms a fundamental concept in our understanding of purinergic secretion. Sensory nerves, adrenal cells, platelets, leucocytes, erythrocytes, mast cells, fibroblasts and endothelial cells have all now been shown to release purines under physiological and pathological conditions [6, [10] [11] [12] [13] [14] [15] ; these, in turn, can stimulate the purine receptors located on these or adjacent cells in an autocrine or paracrine fashion.
There are two principal classes of purinergic receptors, termed P1 or adenosine receptors and P2 receptors, that recognize mainly ADP, ATP, UDP and UTP [16] . This classification was based on a number of observations, including the relative potencies of adenosine and adenine nucleotides, antagonism of the effects of adenosine by methylxanthines, activation of adenylate cyclase by adenosine and induction of prostaglandin synthesis by ADP and ATP. This division remains a fundamental part of purine receptor classification, although both classes are now characterized principally according to their molecular structures and pharmacological profiles.
Adenosine receptors have been subdivided further into A 
#B
receptors are conventionally thought of as low-affinity receptors [17, 18] . In this manner the local concentration of adenosine at the cell surface under physiological or pathological conditions will be a crucial determinant of which receptor is activated.
The signal transduction pathways activated by each receptor are, in part, attributable to coupling to different G-proteins. These responses include principally the inhibition or stimulation of cAMP and the activation of phospholipase C (PLC), inositol 1,4,5-trisphosphate (IP $ ) and diacylglycerol (' DAG '), and subsequent intracellular Ca# + mobilization. In addition the A " receptor is associated with the activation of K + channels and the inhibition of cell-surface Ca# + currents. All adenosine receptors are now known to modulate the mitogenactivated protein (MAP) kinase family of signal transduction proteins [19] . The classification of adenosine receptors and their associated signal transduction systems are summarized in Table 1. P2 receptors are divided into two families, either ligand-gated cation channels or G-protein-coupled receptors, that are termed P2X and P2Y respectively. Subtypes within each family are classified according to the molecular structure, and their nomenclature is identified by a different numerical subscript (i.e. P2X n or P2Y n ). To date, approximately eight mammalian P2X receptors (with several splice variants) and 11 P2Y receptors have been cloned and expressed [20] . Of these, however, only seven P2X receptors (P2X
P2Y "" and P2Y "# ) can induce functional responses. In this review, we will examine the distribution and function of P1 (or adenosine) and P2 receptors in the pituitary gland and consider the implications of these findings for the regulation of pituitary cell function in physiological and pathophysiological states.
DISTRIBUTION OF PURINERGIC RECEPTORS IN THE PITUITARY GLAND P1/adenosine receptors in the pituitary gland
Following the discovery of adenosine receptors in the brain [21] , a number of groups demonstrated that adenosine inhibits neurotransmitter release by binding to presynaptic A " adenosine receptors [22, 23] . The identification of adenosine deaminase, which catalyses the deamination of adenosine to inosine, in the basal hypothalamus of the rat [24] led to the hypothesis that adenosine might act as a neurotransmitter within the hypothalamus or alternatively might regulate pituitary hormone secretion via release into the portal circulation. Adenosine receptors were first described in the anterior and later the posterior pituitary gland in the mid 1980s when Anand-Srivastava and co-workers [25, 26] demonstrated the presence of adenosine-sensitive adenylate cyclase in primary rat pituitary cultures. These receptors were termed ' Ra ' (now named A # ) on the basis that agonists stimulated cAMP with an order of potency of 5h-N-ethylcarboxamidoadenosine (NECA) L-N'-phenylisopropyladenosine (' PIA ') 5h-N-methylcarboxamidoadenosine (' MECA '). This same group later showed that adenosine, in low micromolar concentrations, stimulates the release of adrenocorticotrophic hormone (ACTH ; corticotropin) from cultures of primary rat anterior pituitary cells via the A # receptor [27] . A number of investigators simultaneously examined the effects of adenosine on pituitary physiology using rodent cell lines and rat hemipituitaries as suitable models of pituitary disease. Adenosine had been shown previously [28] to stimulate growth hormone (GH) synthesis and reverse the apomorphine inhibition of prolactin (PRL) synthesis in rat hemipituitaries, but these effects were only apparent at very high concentrations of the nucleoside (2.5 mM) and were mimicked by guanosine. Dorflinger and Schonbrunn [29] examined the ability of adenosine to regulate PRL and GH secretion by the GH % C " rat pituitary tumour cell line. Adenosine ( 50 µM) inhibited PRL and GH secretion from these cells. The abolition of this inhibition by adenosine deaminase and the secretion of biologically effective concentrations of adenosine in these cells, as determined by HPLC, suggested that adenosine produced in culture tonically inhibited hormone release. They also concluded that adenosine induced this response by activation of an A " adenosine receptor on the basis that the selective A " agonist R-N'-phenylisopropyladenosine (R-PIA) inhibited GH and PRL release and vasoactive intestinal peptide (VIP)-stimulated cAMP production. These authors also demonstrated that dipyridamole, an adenosine transport inhibitor, failed to reduce adenosine inhibition of PRL release, suggesting that adenosine was acting via an external receptor. This was the first description of functional A " adenosine receptors in pituitary cells.
Delahunty and co-workers [30] expanded on these observations when they described the presence of functional A " adenosine receptors in the related GH $ rat pituitary tumour cell line. In addition to inhibiting cAMP production, adenosine and stable A " receptor agonists were shown to modify thyrotrophin-releasing hormone (TRH)-stimulated IP $ accumulation in these cells, suggesting that the regulation of TRH-stimulated GH and PRL release described previously by Dorflinger and Schonbrunn in GH % C " cells [29] might be mediated via the PLC rather than the adenylate cyclase pathway. Scorziello et al. [31] demonstrated that the A " adenosine receptor in rat lactotrophs is coupled to both adenylate cyclase and PLC. However, they were unable to confirm the ability of adenosine to modify the TRH-induced increase in intracellular Ca# + concentration, which had been suggested previously in GH receptors to A-type K + channels may, however, be specific to the frog melanotroph.
In contrast with the A " adenosine receptor, the distribution of other adenosine receptor subtypes in the pituitary gland is less well described. A #A receptor gene expression has been reported to occur transiently during the embryological development of the anterior and intermediate lobes of the pituitary gland [39] . The distribution of the A #B receptor, cloned by Stehle and coworkers [40] , was examined by Northern-blot analysis and transcripts were found to be present in the pituitary gland. There are no reports of A $ adenosine receptor mRNA or protein expression in the pituitary gland, although transcripts have been detected by reverse transcriptase (RT)-PCR in every brain region studied in the rat [41] .
It is clear from these studies that A " and, to a certain extent, A # adenosine receptors are expressed in the pituitary gland, but their precise location (i.e. which cell types) had not been defined. We attempted to address these limitations by studying the distribution of A 
P2 receptors in the pituitary gland
ATP and other adenine nucleotides are involved in the regulation of a diverse range of physiological functions in a number of tissues, including endocrine glands, such as the adrenal medulla and endocrine pancreas. In fact, ATP is co-stored and co-released with the products of adrenal chromaffin cells [44, 45] and pancreatic β-cells [46, 47] . Studies demonstrating activation of several second messengers by extracellular ATP in both these endocrine cell types [46, 48] suggest that the nucleotide can play a paracrine role in endocrine cell regulation.
Further evidence of such a paracrine pathway in the neuroendocrine system is indicated by the observations that ATP induces increases in cytosolic Ca# + in hypothalamic neurons [49] and stimulates IP $ production in heterogeneous preparations of sheep pituitary cells in primary culture [50, 51] . Chen and co-workers [52] elaborated on these findings by using real-time imaging of fura 2 fluorescence at the single cell level to show that ATP causes a rapid rise in cytosolic Ca# + in approx. 30 % of primary rat anterior pituitary cells in culture. Furthermore, they were able to identify gonadotrophs as one of the target cells for ATP action and showed that the intracellular Ca# + responses were mediated by G-proteincoupled Ca# + -mobilizing membrane ATP receptors of the P2U subtype (now reclassified as P2Y # receptors). The physiological importance of this observation was highlighted by the subsequent discovery that ATP (and UTP) could stimulate the release of luteinizing hormone (LH) from superfused pituitary cells through this class of receptor [53] .
The observation that ATP could be released from pituitary cells by treatment with a Ca# + ionophore also implied that ATP and other nucleotides could have important paracrine and\or autocrine effects within the pituitary gland [53] . Using gonadotroph-derived αT3-1 cells, Chen and co-workers [54] also examined the signal transduction pathways involved in mediating the action of ATP in gonadotrophs. They were able to demonstrate that extracellular ATP caused a biphasic increase in cytosolic Ca# + with no apparent change in the levels of cAMP or cGMP. Furthermore, the intracellular Ca# + increase was mediated via a pertussis toxin-insensitive and PLC-coupled G-protein and consisted of Ca# + release from an intracellular pool in addition to Novel insights into how purines regulate pituitary cell function channels and adenylate cyclase (AC) in rodent pituitary endocrine cell lines (GH 3 , GH 4 , GH 4 C 1 and AtT20). The A 1 receptor (A 1 R) has also been shown to be in a lowaffinity conformation in these cells. A 1 receptors may also couple to K + channels, but this may be specific to the frog melanotroph. The A 2B receptor appears to be the predominant functional adenosine receptor expressed in primary anterior pituitary cell cultures and studies have shown this receptor to be expressed principally in folliculostellate cells. mRNA and protein expression of this receptor subtype is also detectable in folliculostellate cells. DAG, diacylglycerol ; ERK1/2, extracellular-signalregulated kinase 1/2 ; JNK, c-Jun N-terminal kinase ; PKC, protein kinase C.
Ca# + influx via high-voltage-gated Ca# + channels. These studies also provide the first evidence for protein kinase C (' PKC ') ε translocation by ATP receptors. A pituitary ATP receptor gene was subsequently cloned from a rat pituitary cDNA library and functionally characterized as a P2Y # receptor [55] . The pharmacological characteristics of this receptor closely resembled those of the P2Y # receptors described previously in primary rat gonadotrophs [52] and mixed sheep pituitary cells [50] .
Other studies have highlighted the complexity of purinergic signalling in the pituitary gland by demonstrating expression of a number of P2 purinergic receptors in a variety of pituitary cell types. The ability of ATP to signal through a P2X receptor in gonadotrophs, for example, was suggested by Tomic and co-workers [56] and later confirmed by Villalobos et al. [57] . These investigators also demonstrated that ATP increased cytosolic Ca# + concentration in a large percentage of all anterior pituitary endocrine cell types, i.e. lactotrophs, somatotrophs, corticotrophs and thyrotrophs as well as gonadotrophs. Furthermore, their observations suggested not only that these responses were mediated by at least two different ATP receptors, the ionotropic (P2X # ) and metabotropic (P2Y # ) subtypes, but also that the receptor distribution was not homogeneous among the different pituitary cells. In addition, they were unable to exclude the presence of other ATP receptors, such as P2Y " receptormediated responses were also detected in the majority of lactotrophs and co-expression of these receptor subtypes was common. In contrast, the expression of receptors for ATP in pituitary somatotrophs and gonadotrophs was comparatively simple, both cell types elaborating only P2X #a and P2X #b receptors. P2X receptors were also identified, but not analysed in detail, in corticotrophs and thyrotrophs [62] . In addition to a cell-type-specific expression pattern, these receptors also exhibited differences with respect to their peak amplitude and duration of Ca# + response, enabling specificity of function to be developed within the pituitary gland in response to a common agonist.
As with the adenosinergic signalling system in the pituitary, receptors for adenine nucleotides have also been described recently in folliculostellate cells [63] . In primary rat folliculostellate cells, ATP and UTP, but not adenosine or ADP, induced a biphasic rise in intracellular Ca# + by activating PLC. These actions on Ca# + currents were probably mediated via a P2Y purinergic receptor as In contrast, lactotrophs express mRNA transcripts for P2X 3 , P2X 4 and P2X 7 , and studies have confirmed the functional nature of the latter. P2X purinergic receptors have also been identified in corticotrophs and thyrotrophs, although the subtype of receptor has not been determined. they were reversed in the presence of a P2Y receptor antagonist. Although the subtype of P2Y receptor was not identified in this particular study, the results strengthen the hypothesis that purines exert important paracrine and\or autocrine roles within the anterior pituitary. A summary of the expression pattern of P2 purinergic receptors in the pituitary gland is illustrated in Figure 3 .
BIOLOGICAL EFFECTS OF PURINES IN THE PITUITARY GLAND Effects on pituitary hormone release
Indirect evidence for the existence of adenosine receptors in pituitary cell types other than those discussed previously has come from in vitro and in vivo experiments examining hormonal responses to selective adenosine receptor agonists and antagonists. For example, the effects of xanthines, such as caffeine, theobromine and denbufylline, which act as adenosine receptor antagonists, have been examined. These compounds have been shown to increase ACTH and corticosterone, while lowering thyroid-stimulating hormone (TSH ; thyrotrophin) and GH concentrations [64] [65] [66] . Xanthines, however, also act as potent inhibitors of phosphodiesterases and it is likely that much of their activity in the pituitary gland relates to inhibition of these enzymes as much as blockade of adenosine receptors [66] .
A number of authors have shown that peripheral [67] or central [68] administration of adenosine can stimulate the release of PRL but not LH [68] or TSH [69] . These data, however, gave little insight into the site or mode of action of adenosine in the neuroendocrine system, and could in fact represent non-specific stressful actions. Adenosine produced locally in the pituitary gland could have quite different actions. The inhibitory effects of adenosine on GH and PRL release from cell lines discussed above [29] [30] [31] supported this contention, as did the inhibition by adenosine of LH [70] and folliclestimulating hormone (' FSH ') [70, 71] release from pituitary segments. Further studies using rat pituitary segments showed that adenosine stimulated the release of ACTH [72] , supporting the observations of AnandSrivastava et al. [27] , where primary rat pituitary cultures as opposed to pituitary segments were used. The effects on PRL release, however, are controversial. In contrast with earlier studies [29] [30] [31] , Picanco-Diniz et al. [70] and Yu et al. [71] described a dose-dependent increase in PRL secretion in response to low concentrations of adenosine (10 −"! to 10 −& M). The latter group concluded that these stimulatory effects were mediated via activation of the A " receptor subtype on account of specific inhibition by selective A " receptor antagonists. However, Kumari and co-workers [73] , who also used rat anterior pituitary segments as their chosen experimental model, concluded that adenosine tonically suppresses PRL (and TSH) release via the A " receptor, but activation of the A #A receptor enhanced the release of both hormones. These discrepancies are not easily reconciled, as similar techniques were used in each case. Nevertheless, these studies highlight the importance of analysing such responses in the correct context and emphasize the need for a more detailed description of the expression patterns of adenosine receptors in endocrine and non-endocrine pituitary cells. The use of specific cell lines as opposed to mixed cell cultures may provide more precise information on the localization and function of specific adenosine receptors.
More recently, adenosine was identified as an agonist of the GH secretagogue (GHS) receptor [74] following HPLC fractionation of crude hypothalamic extracts and screening of the fractions for cytosolic Ca# + -generating activity in cells which expressed recombinant GHS receptor but were devoid of adenosine receptors. The authors showed that adenosine as well as the A " receptor agonist R-PIA induced Ca# + responses in these cells. They showed additionally that radiolabelled adenosine bound to these cells and the GHS receptor antagonist inhibited adenosine-, R-PIA-and GHS-induced Ca# + responses at similar IC &!
. In vitro studies, however, failed to show any effects of adenosine or R-PIA on GH secretion either basally or during stimulation by a GH secretagogue (GH-releasing peptide-6) or GHreleasing hormone (' GHRH '). These findings raise doubts as to the physiological relevance of adenosine as a stimulator of GH release in the pituitary.
The effects of P2 purinergic receptor activation on hormone release in anterior pituitary cells have also been examined. In addition to the ATP-and UTP-induced stimulation of LH release from superfused pituitary cells [53] , studies have also shown that ATP is able to function as a local regulator of PRL secretion [75] . ATP secretion was shown in the latter study to be induced or inhibited respectively, following stimulation of primary pituitary cultures by the lactotroph-selective secretagogues TRH and bromocriptine. Moreover, ATP was found to stimulate the release of PRL from most lactotrophs and removal or antagonism of ATP resulted in a reduction in basal or TRH-stimulated PRL release. These observations suggested that ATP can prolong the PRL secretory response elicited by traditional hypophyseal signals. The physiological relevance of this system is highlighted further by the observation that maximal concentrations of ATP were as effective in evoking PRL release as comparable concentrations of TRH. Despite evidence for expression of P2X receptors in somatotrophs, thyrotrophs and corticotrophs [62] , there are no reports to date of the effects of purine nucleotides on hormone release in these cells. were more refractory to TRH-induced PRL release than the overall cell population, these authors proposed that adenosine acts in the pituitary to permit cells to remain longer in a state (G !/ G "
Effects on pituitary cell proliferation
) that is more refractory to secretory signals.
Lewis and co-workers [81] also examined the effects of adenosine on cell proliferation in GH $ cells. They showed that high concentrations of adenosine (100 µM or above) inhibited the proliferation of these cells, an action they attributed to an intracellular rather than a receptormediated site of action, as the effects were reversible by the adenosine transport inhibitor dipyridamole. Analysis of the treated population of cells showed an increase in DNA laddering in comparison with controls, with no differences in the proportion of cells in the various phases of the cell cycle, suggesting that adenosine reduced proliferation in GH $ cells by increasing the rate of apoptosis. Epidermal growth factor (EGF), by preventing apoptosis, was found to restore the growth rate of the adenosine-treated cells to that observed in the control population. Other researchers have also shown that EGF can interact with the adenosine signalling system in the pituitary. For example, EGF has been shown to modify A " adenosine receptor expression in a rat pituitary tumour cell line [82] , suggesting that distinct signalling pathways can interact dynamically to regulate pituitary cell function. The data from these studies suggest that adenosine can modify pituitary cell proliferation by at least two apparently unrelated mechanisms.
Our recent observations [43] have indicated that adenosine can regulate proliferation in rat pituitary tumour GH $ cells by another mechanism. In these cells and in murine pituitary AtT20 cells, adenosine and the selective A " adenosine receptor agonist 2-chloro-N'-cyclopentyladenosine (' CCPA ') at high concentration inhibited cell growth. We showed that this inhibition was mediated in GH $ cells by a slowed progression through the phases of the cell cycle rather than through a cellcycle-stage-specific arrest. In contrast with pituitary endocrine cells, we showed that adenosine, at physiological concentrations (up to micromolar) and acting through a different adenosine receptor subtype (A #B ), caused a dose-dependent stimulation of growth in a pituitary folliculostellate cell line (TtT\GF). These findings suggest that adenosine may play a significant role in regulating the trophic activity of folliculostellate cells within the anterior pituitary.
Effects of adenosine on interleukin (IL)-6 and vascular endothelial growth factor (VEGF) production within the anterior pituitary
The above descriptions provide a complex picture of purinergic signalling pathways in the pituitary gland. P2 purinergic receptors are widely distributed, but seem to show cell-type-selectivity both in the pattern and quantity of receptor expression [62, 63] . Similarly, we [43] and others [29] [30] [31] [32] [33] [34] have shown that adenosine receptors are also preferentially expressed within pituitary cell subpopulations. Our investigations have suggested that the A #B receptor, in particular, is the physiologically dominant adenosine receptor in the pituitary. The demonstration of its preferential expression in folliculostellate cells raises intriguing questions as to its role in these cells.
Pituitary folliculostellate cells, with their characteristic star-shaped morphology, were first described in the pituitary in 1953 [83] . Until recently, they were thought to be non-secretory and their proposed function remained obscure. A number of investigators, however, have shown that folliculostellate cells produce bioactive molecules which are not secreted into the bloodstream as hormones, but act locally as paracrine and\or autocrine factors, modulating the function of hormone-secreting cells and other cell types such as the endothelium [42, 84, 85] . These paracrine effects of folliculostellate cells on neighbouring endocrine cell function have been studied extensively. They include enhancement of basal and TRH-stimulated PRL secretion by GH $ cells [86] , mediation of the inhibitory effects of interferon-γ (IFN-γ) on the stimulated release of ACTH, PRL and GH in primary pituitary cultures [87] and release of the proinflammatory cytokine IL-6 in response to VIP [88] and pituitary adenylate cyclase-activating polypeptide (' PACAP ') [89] . In addition, IL-6 is well known to stimulate the release of PRL, GH, LH and folliclestimulating hormone in vitro [90, 91] and ACTH in vivo [92] . The ability of folliculostellate cells to respond to IFN-γ and produce IL-6 highlights the key role that these cells are now known to play in regulating cross-talk between the neuroendocrine and immune systems.
In this context, it is interesting to note that adenosine has been shown to stimulate IL-6 release in primary anterior pituitary cell cultures [93] . Our recent studies have examined this relationship in more detail. We have shown that adenosine, via the A #B receptor, potently stimulates IL-6 release from folliculostellate cell cultures, mediated via adenylate cyclase and PLC coupled to p38 MAP kinase (D. A. Rees, B. M. Lewis, K. Francis, T. Easter, M. F. Scanlon and J. Ham, unpublished work). Similar but significantly lower magnitude responses were observed on VEGF release, but these latter findings may represent an autocrine effect of IL-6 [94] . The production of both IL-6 and VEGF was reversible by co-incubation with dexamethasone. Double-labelling techniques have shown previously [95] that glucocorticoid receptors are present in folliculostellate cells, and these studies have been supplemented by cell culture-based analyses confirming the presence of functional glucocorticoid receptors through the reversal of dexamethasone effects by the glucocorticoid receptor antagonist RU 486 [96, 97] . The immunosuppressive effects of glucocorticoids are often mediated via transcriptional inhibition of immunologically relevant genes, but it is interesting to note that glucocorticoids have also been reported to decrease A #B adenosine receptor signalling in both Jurkat cells [98] and DDT " MF2 smooth-muscle cells [99] . In the latter, decreased A #B receptor signalling was accompanied by an increase in the number of co-expressed A " receptors. Dexamethasone, therefore, could be modifying the release of these substances by a number of separate mechanisms. As both systemic and locally generated IL-6 can potently stimulate ACTH (and GH, PRL and gonadotrophin) release in the pituitary gland [90] [91] [92] , these results, therefore, suggest that adenosine may have an important role in activation of the pituitary gland in regulating the response of the hypothalamic-pituitary-adrenal axis to inflammation. Whether similar effects can be mediated by P2 purinergic receptors is not known at present, although the development of a murine folliculostellate cell line (Tpit\F1) expressing P2Y # receptors and able to secrete IL-6 [100] could represent an important model for studies in this setting.
PHYSIOLOGICAL AND PATHOLOGICAL CONSIDERATIONS

Co-expression of purinergic receptors
Adenosine and P2 purinergic receptors within the pituitary gland clearly have distinct, but frequently overlapping, tissue distributions. The fact that more than one adenosine or P2 receptor can be expressed by the same cell raises important questions about the functional significance of this co-localization. Given the ubiquitous distribution of purine receptors in the body, it is perhaps not surprising that more than one subtype is often expressed in the same tissue and even the same cell. For example, the expression of more than one subtype of adenosine receptor on the same cell allows the common agonist adenosine to activate multiple signalling pathways. Furthermore, the presence of adenylate cyclase as a common second messenger for all four adenosine receptor subtypes, with negative and positive coupling to the A The relative importance of A #B receptors may be greater in situations characterized by considerable increases in interstitial levels of adenosine, as occurs in hypoxia. There are, however, cellular systems where the actions of A #B receptors appear to predominate [101] , and the discovery in folliculostellate and pituitary endocrine cells of A " receptors with a much lower affinity for adenosine and selective agonists compared with those described elsewhere [17, 18] suggests a functional relevance of the A #B receptor in the pituitary gland. The co-existence of both adenosine and P2 receptors in pituitary cells adds another level of complexity. Such coexpression has been identified for a number of cell types, including mast cells, endothelial cells, smooth-muscle cells and PC12 phaeochromocytoma cells [20] , although the exact functional significance of such co-localization is not clear at present. The co-expression of more than one purine receptor, with their different affinities for the endogenous agonist, also highlights the importance of the local concentration of agonist in physiological and pathological conditions in determining individual receptor activation. The extracellular concentration of adenosine, for example, in rat phrenic motor nerve terminals needed to increase transmitter release via activation of A #A receptors is higher than that required to inhibit neurotransmitter release via A " receptors [102] . Because adenosine is formed as a breakdown product of ATP released from nerve endings, this suggests that the concentration of adenosine is critically related to neuronal activity.
The local concentration of extracellular adenosine is clearly important in determining which adenosine receptor is activated. However, the concentration of purines in the extracellular environment is controlled not only by release from the intracellular space, but also by a series of cell-surface and intracellular enzymes, catalysing the breakdown and synthesis of these compounds and, therefore, limiting their spatiotemporal activity. Several of these enzymes have been characterized and those involved in the metabolism of adenosine include ecto5h-nucleotidase (which catalyses the hydrolysis of AMP to adenosine), intracellular and extracellular adenosine deaminase (catalysing deamination of adenosine to inosine) and adenosine kinase (regulating the phosphorylation of adenosine to AMP and expressed in the intracellular space only). The fate of adenosine in any given situation is governed by its concentration, since adenosine kinase and adenosine deaminase have vastly different kinetic properties. At physiological (submicromolar) concentrations of adenosine, phosphorylation is the predominant route of metabolism, whereas adenosine deaminase in most circumstances functions as a highvolume\low-affinity system that is activated when adenosine concentrations increase [103] . In a similar manner, ecto-5h-nucleotidase is ubiquitously expressed, but often differentially regulated in malignant and benign tissue [104] and by cytokines [105] and glucocorticoids [106] , suggesting that local concentrations of purines at the cell surface can be controlled according to the prevailing physiological or pathophysiological circumstances.
These numerous factors combine to determine which adenosine or P2 receptor subtype, or combination of receptors, is activated in any given circumstance and dictate, in combination with the cell distribution of the receptor subtypes, which cellular response is activated.
Implications for pituitary tumorigenesis
Pituitary tumorigenesis is a multifactorial process requiring specific favourable environmental conditions in addition to altered expression of oncogenes or tumour suppressor genes. Adenosine has been proposed as a potential contributor to solid tumour growth on the basis of its cytoprotective, immunomodulatory and growthpromoting properties [103] . It is tempting to speculate, based on the considerations outlined above, that the differential distribution, affinities and functional effects of the A " and A #B receptors may have a relevance to pituitary tumour formation and\or maintenance. Hypoxia is a major stimulus to the release of adenosine [7] . Under these circumstances micromolar concentrations of the nucleoside typically accumulate [107] . Solid tumours of all types are characterized by their hypoxic cores and it is conceivable that adenosine and other purines accumulate in the interstitium of such tumours in high concentration. Pituitary tumours are less vascular than the normal pituitary gland [108] , suggesting that hypoxia may be a particular feature of these neoplasms. Under these conditions, the hypoxia-induced release of adenosine as an adaptive response of the cell to metabolic demands could indirectly contribute to the proliferation of transformed pituitary cells. Should the distribution and the relative affinities of the adenosine receptors identified in our recent study [43] be mirrored in vivo, then folliculostellate A #B adenosine receptors would be preferentially activated, resulting not only in folliculostellate growth, but also indirectly in vascular and endocrine cell proliferation induced by VEGF and IL-6 release. The importance of IL-6, in particular, as a pituitary tumour-progression factor has received much attention recently. It is known to stimulate hormone release not only from normal pituitary cells [90] [91] [92] , but also from pituitary tumours placed in culture [109] . Furthermore, IL-6 stimulates the growth of pituitary tumour cells [110] and IL-6 expression in pituitary tumours correlates with biological aggression [111] , raising the possibility that local IL-6 levels could be an indirect marker of tumour size, hypoxia and adenosine concentration.
There are, of course, a number of assumptions made in the above hypothesis, not least being the relevance of folliculostellate cells to the pathogenesis of pituitary adenomas. IL-6 is known to be a growth factor for TtT\GF folliculostellate cells [94] and GH $ and MtT\E pituitary tumour cell lines [110, 112] . However, whether the growth stimulatory effect of IL-6 on TtT\GF cells is specific for transformed folliculostellate cells or also occurs in normal cells remains to be determined. Nonfunctioning pituitary tumours that arise as a result of the clonal expansion of mutated folliculostellate cells and consisting mainly of transformed folliculostellate cells (TtT\GF) are rare [113] and it may be that the autocrine stimulatory effect of IL-6 is only relevant in these cells. With respect to endocrine cells, evidence for the importance of folliculostellate cells in pituitary tumour formation comes from the induction of lactotroph adenomas by oestrogen in Fischer rats, where adenoma formation is accompanied by an activation of folliculostellate cells [114] . Oestrogen has also been shown to induce the expression of the immediate early gene, c-fos, in folliculostellate cells and lactotrophs [115] , possibly indicating direct responsiveness of folliculostellate cells to oestradiol treatment. The observation that folliculostellate cells mediate the transforming-growth-factor-(' TGF-β3 ')-induced growth of pituitary lactotrophs [116] supports an important role for these cells in lactotroph cell growth. In addition, folliculostellate-like TtT\GF cells have been shown to be essential to the formation and growth of MtT\S pituitary tumours in nude mice [117] . These observations suggest that folliculostellate cells play an important role in pituitary adenoma formation, perhaps by regulating the production of angiogenic factors, such as VEGF or basic fibroblast growth factor (bFGF), and\or regulators of the extracellular matrix, such as tissue inhibitors of metalloproteinases (' TIMPs ') [118] .
The relevance of folliculostellate cells to pituitary tumour pathogenesis is cast into doubt, however, by the observation that they occur only rarely [119] , although it is interesting to note that, at the border between the normal pituitary and the adenoma, a transition zone often exists which is particularly rich in folliculostellate cells [119, 120] . The source of IL-6 in pituitary adenomas is also an area of controversy. As folliculostellate cells seem to be rare in adenoma tissue and may be immunonegative for IL-6 [121] , it may be that the neoplastic endocrine cells are the source of IL-6 [122] . However, this does not exclude an important role for folliculostellate cells in supporting the growth of pituitary tumours, as the IL-6 produced by tumour cells could stimulate the proliferation of the normal folliculostellate cells in the transition zone and increase their production of growth-supporting substances such as VEGF and bFGF. The folliculostellate-cell-derived VEGF and bFGF could then diffuse, or be carried in the blood supply, to the tumour where it could promote angiogenesis. Therefore, during tumour initiation, the border of the adenoma could represent the principal site of initiation and regulation of angiogenesis. This concept is similar to that proposed by Fukumara and co-workers [123] , who speculated that fibroblasts on the tumour edge are the most important source of VEGF during formation of some types of tumours.
Possible roles in inflammatory and stress responses
It has become increasingly clear that adenosine exerts important effects in the regulation of immune responses in a number of cell systems. Numerous reports have alluded to its immunosuppressive and anti-inflammatory properties, which include inhibition of pro-inflammatory IL-2, tumour necrosis factor (' TNF ')-α and macrophage inflammatory protein (' MIP ')-1α synthesis [124] [125] [126] , induction of anti-inflammatory IL-10 synthesis [125] , general inhibition of T-cell activation and expansion [127] , inhibition of neutrophil superoxide formation [128] and a reduction in neutrophil accumulation at sites of inflammation [129] . In addition, many drugs with potent anti-inflammatory activities often exert their therapeutic benefit by increasing adenosine concentration. Methotrexate, for example, is thought to inhibit neutrophil function by stimulating adenosine release from connective tissue cells [130] , and sulphasalazine increases adenosine secretion at sites of inflammation [131] .
A Adenosine binds to folliculostellate A 2B receptors (A 2B R) to stimulate IL-6 release via adenylate cyclase and PLC coupled to p38 MAP kinase. IL-6 induces ACTH secretion from corticotrophs which, in turn, stimulates corticosteroid release from the adrenal cortex. Glucocorticoids bind to nuclear glucocorticoid receptors (GR), present in both folliculostellate and corticotroph cells, to regulate this response in a negative feedback pattern. Bacterial LPS stimulates IL-6 release from folliculostellate cells via the toll-like receptor-4 (Tlr-4). We postulate that this pathway may generate increased extracellular adenosine which could augment the release of IL-6 further.
A # , notably A #B , receptor expression in pituitary folliculostellate cells [43] suggests that this receptor may have an immunomodulatory role in the pituitary gland. Folliculostellate cells secrete a number of growth factors and cytokines, such as IL-6, TNF-α, VEGF and bFGF [85, 96, 97] , which appear to regulate pituitary function by playing a supportive role for neighbouring endothelial and endocrine cells. These properties of folliculostellate cells, coupled with the fact that they possess receptors for bacterial LPS [97] , complement C3a (K. Francis, B. M. Lewis, H. Akatsu, P. N. Monk, S. A. Cain, M. F. Scanlon, B. P. Morgan, J. Ham and P. Gasque, unpublished work) and glucocorticoids [95] , suggest that they co-ordinate the bidirectional exchange of information between the immune and endocrine systems and can regulate stress and inflammatory responses [133] . Maintaining this interaction is critical for homoeostatic regulation and resistance to disease. IL-6, in particular, may play an important role as a linking molecule between the folliculostellate and endocrine cells in the anterior pituitary, since it has been shown to regulate GH, PRL and ACTH secretion [90] [91] [92] . Our observation (D. A. Rees, B. M. Lewis, K. Francis, T. Easter, M. F. Scanlon and J. Ham, unpublished work), therefore, that adenosine stimulates IL-6 secretion via the A #B receptor linked to the adenylate cyclase and PLC pathways coupled to p38 MAP kinase adds to the anti-inflammatory roles for the nucleoside described elsewhere. The enzymes involved in the p38 MAP kinase pathway are transducers of stress responses that are activated by ultraviolet light, cytokines and osmotic shock [134, 135] . The coupling of adenosine to p38 MAP kinase and IL-6 secretion, together with its suppression in the presence of corticosteroids, indicates a role of adenosine and folliculostellate cells in inflammation, stress and hypoxia. We hypothesize that folliculostellate cells respond to a variety of immune molecules and endotoxins, resulting in accumulation of extracellular adenosine [71, 136] and an autocrine stimulation of IL-6 and VEGF to modulate inflammatory processes and stimulate steroidogenesis. These possible mechanisms are outlined in Figure 4 .
CONCLUSION
Extracellular purines mediate a diverse variety of biological responses in a wide range of tissues. The distribution of purine receptors reflects this diversity and is illustrated particularly well in the pituitary gland, where recent evidence has emerged to suggest that specificity of function can be determined by cell-selective expression. These observations have also revealed a wide diversity of effects on several aspects of pituitary function, including trophic effects, actions on hormone release and roles in cytokine synthesis, with resultant implications for pathological in addition to physiological states. Future research may expand on these observations and go on to determine the integrated pattern of events arising from differential activation and desensitization or up-regulation of coexisting receptors under conditions of different concentrations of agonist in the pituitary. Such developments may pave the way for an improved understanding of the role of purines in pituitary physiology and disease, and could offer important advances for future therapies. 
